Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319995 | 0.87 | CYP2C9 (0.50) | SIGMAR1MEN1KMT2AMAPTCYP2C9 | |
| SCHEMBL4319992 | 0.87 | CYP2C9 (0.50) | SIGMAR1MEN1KMT2AMAPTCYP2C9 | |
| SCHEMBL13892385 | 0.87 | CYP2C9 (0.50) | SIGMAR1MEN1KMT2AMAPTCYP2C9 | |
| SCHEMBL14047566 | 0.79 | HTR2C (0.41) | FAAHSIGMAR1HTR2CPOLBMEN1 | |
| SCHEMBL15516474 | 0.74 | L3MBTL1 (0.58) | FAAHSIGMAR1HTR2CKMT2AL3MBTL1 | |
| SCHEMBL30799059 | 0.72 | L3MBTL1 (0.65) | FAAHSIGMAR1HTR2CL3MBTL1 | |
| SCHEMBL31512198 | 0.71 | L3MBTL1 (0.68) | FAAHSIGMAR1HTR2CKMT2AL3MBTL1 | |
| SCHEMBL27165584 | 0.71 | L3MBTL1 (0.68) | FAAHSIGMAR1HTR2CKMT2AL3MBTL1 | |
| SCHEMBL30799033 | 0.68 | CYP11B2 (0.41) | FAAHSIGMAR1HTR2CPOLBMEN1 | |
| SCHEMBL27385984 | 0.68 | CYP11B2 (0.41) | FAAHSIGMAR1HTR2CPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161311-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161311-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | DNTT, PNP, NNMT | FAAH 3824/4885SIGMAR1 2167/4885HTR2C 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.